Johnson & Johnson (ETR:JNJ)
154.68
+2.18 (1.43%)
Feb 21, 2025, 5:35 PM CET
Johnson & Johnson Revenue
In the year 2024, Johnson & Johnson had annual revenue of $88.82B USD with 4.30% growth. Johnson & Johnson had revenue of $22.52B in the quarter ending December 29, 2024, with 5.26% growth.
Revenue
$88.82B
Revenue Growth
+4.30%
P/S Ratio
n/a
Revenue / Employee
$643.16K
Employees
138,100
Market Cap
373.88B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 22.67B |
Merck KGaA | 20.96B |
Bayer Aktiengesellschaft | 46.74B |
Fresenius SE & Co. KGaA | 22.81B |
Sartorius Aktiengesellschaft | 3.38B |
Fresenius Medical Care AG | 19.24B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Johnson & Johnson News
- 4 hours ago - Johnson & Johnson's TREMFYA® Achieves Key Milestones in Ulcerative Colitis Treatment - GuruFocus
- 1 day ago - Final Trade: TEVA, JNJ, TJX, BABA - CNBC
- 1 day ago - JNJ met main goal in late-stage trial for ulcerative colitis treatment - Seeking Alpha
- 1 day ago - TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis - Benzinga
- 1 day ago - TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis - PRNewsWire
- 1 day ago - Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - Reuters
- 2 days ago - Johnson & Johnson (JNJ) Completes Public Offerings of Notes - GuruFocus
- 3 days ago - AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant - Seeking Alpha